4.7 Article Proceedings Paper

Complex networks reveal early MRI markers of Parkinson's disease

Journal

MEDICAL IMAGE ANALYSIS
Volume 48, Issue -, Pages 12-24

Publisher

ELSEVIER
DOI: 10.1016/j.media.2018.05.004

Keywords

Parkinson's disease; MRI; Complex networks; Machine learning

Funding

  1. Michael J. Fox Foundation for Parkinson's Research
  2. AbbVie
  3. Avid Radiopharmaceuticals
  4. Biogen Idec
  5. Bristol-Myers Squibb
  6. Covance
  7. GE Healthcare
  8. Genentech
  9. Glaxo-SmithKline
  10. Eli Lilly and Company
  11. Lundbeck
  12. Merck Co.
  13. Meso Scale Discovery
  14. Pfizer
  15. Piramal
  16. Hoffmann-La Roche
  17. UCB (Union ChimiqueBelge)

Ask authors/readers for more resources

Parkinson's disease (PD) is the most common neurological disorder, after Alzheimer's disease, and is characterized by a long prodromal stage lasting up to 20 years. As age is a prominent factor risk for the disease, next years will see a continuous increment of PD patients, making urgent the development of efficient strategies for early diagnosis and treatments. We propose here a novel approach based on complex networks for accurate early diagnoses using magnetic resonance imaging (MRI) data; our approach also allows us to investigate which are the brain regions mostly affected by the disease. First of all, we define a network model of brain regions and associate to each region proper connectivity measures. Thus, each brain is represented through a feature vector encoding the local relationships brain regions interweave. Then, Random Forests are used for feature selection and learning a compact representation. Finally, we use a Support Vector Machine to combine complex network features with clinical scores typical of PD prodromal phase and provide a diagnostic index. We evaluated the classification performance on the Parkinson's Progression Markers Initiative (PPMI) database, including a mixed cohort of 169 normal controls (NC) and 374 PD patients. Our model compares favorably with existing state-of-the-art MRI approaches. Besides, as a difference with previous approaches, our methodology ranks the brain regions according to disease effects without any a priori assumption. (C) 2018 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available